3 Prescription Drugs You Didn't Know Come From Marijuana

A close look at three prescription drugs you probably didn't know come from one of the world's most controversial plants: cannabis.

Mar 16, 2014 at 4:15PM

It's no secret that drug discovery is an arduous process; it often takes pharmaceutical companies more than a decade and over $1 billion to bring a new compound to the market. Because of the complexities in discovering new drug candidates from scratch, many biopharmaceutical companies get a head start by drawing inspiration from nature.

Examples of blockbuster drugs that were discovered from obscure natural sources abound, so it should also come as no surprise that scientists are unlocking the therapeutic benefits of what may be today's most controversial plant: marijuana.


Source: GW Pharmaceuticals.

The best-known marijuana extract is the psychoactive compound tetrahydrocannabinol, or THC, but the plant also contains more than 60 lesser-known compounds that belong to the same chemical family as THC. Fledgling biotech GW Pharmaceuticals (NASDAQ:GWPH) is exploring the medicinal potential of some of these chemicals, and some of the world's largest pharma companies, including AbbVie (NYSE:ABBV) and Valeant Pharmaceuticals (NYSE:VRX), market products in this drug class. Let's look at three of the most prominent products, and what investors should watch in the field of marijuana research going forward.

GW Pharmaceuticals' Sativex is currently used to treat spasticity (muscle spasms and stiffness) caused by multiple sclerosis. It is composed of two compounds found in marijuana: THC and cannabidiol, or CBD, which isn't psychoactive. The drug, delivered through a vaporizer, is approved in 25 countries but isn't available in the U.S. just yet.

GW Pharmaceuticals is collaborating with Otsuka Pharmaceutical on clinical trials that could lead to FDA approval, and the duo is also working on clinical studies that could result in expanded approval for the treatment of cancer pain. Phase 3 trial data from some of these studies will be available toward the end of the year, and these results will be important catalysts for GW Pharma's stock.

Marinol and Cesamet
Unlike Sativex, AbbVie's Marinol is FDA-approved for the treatment of nausea in patients undergoing chemotherapy and is also prescribed to AIDS patients suffering from loss of appetite. The drug is made of a synthetic form of THC and is delivered as an oral capsule. Valeant Pharmaceuticals has a similar compound on the market called Cesamet, which also treats nausea in chemotherapy patients.

Interestingly, marijuana is classified as a Schedule I drug by the DEA because it doesn't have a proven medical application and users may abuse the drug. Marinol and Cesamet, however, are listed as Schedule III and Schedule II drugs, respectively, meaning the FDA recognizes their clinical benefits and their abuse potentials are believed to be lower.

Looking ahead
The science behind these compounds is fascinating, but there are a few things investors need to consider when looking at pharmaceutical products derived from cannabis.

First, while these drugs serve critical medical needs, they have been far from blockbusters. AbbVie and Valeant, which both bring in billions of dollars each year in revenue, don't provide sales for their cannabinoid products, suggesting that they only add incrementally to the companies' top lines. GW Pharmaceuticals, which currently markets only Sativex, also hasn't had great results so far. It reported only $12.4 million in sales last quarter, and the drug will need both an expanded label and FDA approval to meaningfully ramp up sales.

Second, while some scientists continue to explore the potential of cannabinoids to treat a wide variety of diseases, few companies are active in this space today. GW Pharma is an exception, and its drug development platform is focused on compounds derived from marijuana. In addition to Sativex, the company is developing Epidiolex for the treatment of rare diseases, and it has other compounds in early-stage clinical trials for autoimmune diseases, diabetes, and schizophrenia.

While GW boasts a large pipeline for a relatively small drugmaker, its shares have soared over the past 12 months, and the company's market cap tops $1 billion. This climb is largely due to swelling valuations across the biotech sector and high expectations for its pipeline. At this valuation, however, it looks like sales of its late-stage experimental drugs are already priced into the stock. Any stumbles in clinical trials, or, if its drugs gain FDA approval, poor commercial drug launches will certainly cool investor enthusiasm.

Don't let your savings go up in smoke
It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.

Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers